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Abstract The place of calcium supplementation, with or
without concomitant vitamin D supplementation, has been
much debated in terms of both efficacy and safety. There have
been numerous trials and meta-analyses of supplementation
for fracture reduction, and associations with risk of myocardi-
al infarction have been suggested in recent years. In this
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report, the product of an expert consensus meeting of the
European Society for Clinical and Economic Aspects of
Osteoporosis, Osteoarthritis and Musculoskeletal Diseases
(ESCEO) and the International Foundation for Osteoporosis
(IOF), we review the evidence for the value of calcium sup-
plementation, with or without vitamin D supplementation, for
healthy musculoskeletal ageing. We conclude that (1) calcium
and vitamin D supplementation leads to a modest reduction in
fracture risk, although population-level intervention has not
been shown to be an effective public health strategy; (2) sup-
plementation with calcium alone for fracture reduction is not
supported by the literature; (3) side effects of calcium supple-
mentation include renal stones and gastrointestinal symptoms;
(4) vitamin D supplementation, rather than calcium supple-
mentation, may reduce falls risk; and (5) assertions of in-
creased cardiovascular risk consequent to calcium supplemen-
tation are not convincingly supported by current evidence. In
conclusion, we recommend, on the basis of the current evi-
dence, that calcium supplementation, with concomitant vita-
min D supplementation, is supported for patients at high risk
of calcium and vitamin D insufficiency, and in those who are
receiving treatment for osteoporosis.
Keywords Calcium supplementation . Fracture reduction .
Myocardial infarction . VitaminD supplementation
Introduction
The skeleton is superbly adapted to its function, combining
strength with lightness. This is achieved through a hierarchical
structure built upon type 1 collagen matrix strengthened with
the apposition of calcium hydroxyapatite crystals [1]. The
presence of calcium mineral as a major constituent of bone
clearly suggests the importance of adequate calcium and vita-
min D status for skeletal health. Whilst dietary calcium intake
and endogenous vitamin D synthesis are sufficient for most
individuals in many populations, there is evidence that sup-
plemental approaches [2–6], particularly targeted to individ-
uals with inadequate calcium and vitamin D status, may ben-
efit bone mass and reduce fracture risk. The interaction be-
tween the skeleton and its associated musculature has been
amply documented, both through direct mechanical and, more
recently, potential hormonal mechanisms. Indeed, there is a
substantial body of preclinical evidence suggesting the impor-
tance of calcium in muscle physiology. Calcium is largely
involved in skeletal muscle regulation and maintenance and
contributes to the neuromuscular command and regulation of
intracellular myosin fibres for skeletal muscle contraction and
relaxation. It is also key to the activation of glycolytic metab-
olism and mitochondrial energy metabolism [7, 8], and there
is evidence that vitamin D contributes to calcium uptake and
regulation in muscle cells [9]. These observations suggest the
importance of calcium not just for bone health but also for
proper function of skeletal muscle. In recent years, the role
of calcium, together with that of concomitant vitamin D sup-
plementation, has come under close scrutiny as a result of
studies suggesting potential adverse cardiovascular effects
from calcium or calcium and vitamin D supplementation.
The purpose of this review is to comprehensively address
the evidence relating to the efficacy and effectiveness of cal-
cium supplementation, either alone or in combination with
vitamin D supplementation, for healthy musculoskeletal age-
ing (primarily fracture reduction) and to critically appraise the
evidence used to support claims of adverse health outcomes
from these interventions.
Burden of disease
Osteoporotic fractures are common, and loss of both bone,
and muscle mass/function (sarcopenia), predispose to these
health-defining events [10, 11]. Thus, in many populations,
the lifetime risk of an incident fracture from the age of 50 years
is 1 in 2 (50 %) for women and 1 in 5 (20 %) for men [10].
Such fractures cost the EU around €39 billion annually [12]
and most major osteoporotic fractures, in addition to causing
substantial disability and morbidity, are associated with an
approximately 20 % reduction in survival relative to non-
fracture controls [10]. The role of calcium supplementation
should be therefore appreciated in the context of a devastating
health outcome, which has massive impact for individuals but
also on healthcare systems and societies as whole.
Calcium, with or without vitamin D,
supplementation for fracture risk reduction
Although several studies, at least in the short term, have indi-
cated positive effects of calcium supplementation on bone
mineral density [13–16], the key outcome in terms of effec-
tiveness is fracture reduction. There have been many
randomised controlled trials of either calcium alone or calcium
in combination with vitamin D for fracture reduction and sev-
eral subsequent meta-analyses seeking to elucidate the overall
effect of this intervention [17–21]. Here, we review separately
the evidence for a benefit of calcium supplementation alone,
and that of calcium with vitamin D supplementation.
Calcium supplementation and fracture risk
Tang et al. [17] undertook a meta-analysis in which studies of
calcium, or calcium and vitamin D, were analysed separately.
The authors identified 17 trials reporting fracture as the out-
come, including 52,625 patients. Importantly, the majority of
patients considered were included in trials of calcium and
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vitamin D supplementation (n = 46,108), with the minority
(n = 6517) included in trials of calcium supplementation
alone. The authors undertook a sensitivity analysis comparing
the effect of either therapeutic approach. The relative risk
(RR) of any fracture with calcium and vitamin D supplemen-
tation was 0.87 (95 % CI 0.77, 0.97), and with calcium alone,
it was 0.90 (95 % CI 0.80, 1.00). Thus, although the effect
sizes were similar for either supplemental approach, the mod-
est relative risk reduction for fracture with calcium alone was
of borderline statistical significance. A further meta-analysis
from Bischoff-Ferrari et al. included hip fracture as an out-
come and noted a potentially increased risk of hip fracture
with calcium alone [18], albeit in a relatively low number of
participants. Finally, Bolland et al. [20] undertook a compre-
hensive systematic review and meta-analysis of associations
between calcium intake (from diet and/or supplementation)
and risk of fracture. The authors identified 26 trials
(n = 69,107) of calcium supplementation, calcium and vitamin
D supplementation or factorial designs using both approaches.
There was no statistically significant interaction between type
of intervention (calcium alone vs calcium and vitamin D) ex-
cept for hip fracture [calcium alone RR, 1.51 (95 % CI 0.93,
2.48); calcium and vitamin DRR, 0.84 (95%CI 0.74, 0.96); p
interaction = 0.02]. Thus, amongst 13 studies of calcium sup-
plementation alone, there was a modest 15 % reduction in risk
of any fracture [RR 0.85 (95 % CI 0.73, 0.98)], but not of hip,
vertebral [RR 0.80 (95 % CI 0.64, 1.01)] or forearm [RR 0.92
(95 % CI 0.69, 1.23)] fractures. It should be noted that owing
to the design of the original trials, the studies included in the
analysis of individual fracture outcomes differed by fracture
type.
Calcium with vitamin D supplementation and fracture
risk
The DIPART Investigator group undertook an individual pa-
tient data (IPD) meta-analysis of 68,500 patients from seven
individual randomised controlled trials [19]. The included
studies varied in terms of setting, with the majority being
community-based, but two were set in residential/nursing
homes. Duration of follow-up varied from 18 to 85 months,
and population sizes ranged from 1144 to the largest
[Women’s Health Initiative (WHI)] comprising 36,282 wom-
en. For the combined use of calcium and vitamin D, there was
a modest reduction in all fractures [HR 0.92 (95 % CI 0.86,
0.99)] and hip fractures [HR 0.83 (95 % CI 0.69, 0.99)].
Sensitivity analyses in which various individual studies were
omitted gave similar results. Importantly, the DIPART study
included participants from both institutions and the communi-
ty, and indeed the calcium and vitamin D trial participants
were all community dwelling, so these results suggest efficacy
of the intervention in the free-living setting.
A similar effect size for calcium and vitamin D on frac-
ture risk reduction was found in a recent trial-level meta-
analysis undertaken for the US National Osteoporosis
Foundation [21]. There were eight included studies
comprising a total of 30,970 participants and reporting
195 hip fractures and 2231 total fractures. The authors used
a random effects model to calculate summary relative risk
estimates (SRRE) for total fractures and hip fractures, find-
ing a 15 % reduction in total fractures [SRRE 0.85 (95 % CI
0.73, 0.98)] and a 30 % reduction in hip fracture [SRRE
0.70 (95 % CI 0.56, 0.87)]. Given the often poor compli-
ance with calcium supplementation the authors elected to
focus primarily on per protocol analyses where possible, on
the very reasonable basis that the treatment will not work if
it is not taken. This approach can be criticised in deviating
from an intention to treat (ITT) analysis but is clearly ap-
propriate in the context of establishing a biological effect,
as opposed to real world effectiveness: issues of gastroin-
testinal side effects and poor compliance, which are
discussed separately, are clearly relevant here. In order to
counter the potential issue of unbalanced randomisation
groups consequent to the use of per protocol rather than
ITT approaches, relative risk estimates accounting for po-
tential confounders were used where possible. Two of the
included studies were institution-based and the remainder
included community-dwelling individuals. The authors un-
dertook multiple sensitivity analyses including removal of
individual studies, which is important as WHI and
RECORD were included, and observed similar results.
In the meta-analysis of Bolland [20], there was a risk re-
duction for all fractures [RR 0.92 (95 % CI 0.86, 0.99)] and
hip fractures [RR 0.84 (95 % CI 0.74, 0.96)] with combined
calcium and vitamin D administration. Analysed together,
supplementation with calcium or calcium and vitamin D was
associated with a reduction in all fractures [RR 0.89 (95 % CI
0.81, 0.96)] and vertebral fractures [RR 0.86 (95 % CI 0.74,
1.00)], but not forearm fractures [RR 0.96 (95 % CI 0.85,
1.09)] or hip fractures [RR 0.95 (95 % CI 0.76, 1.18)].
Importantly, the authors meta-analysed groups of studies by
risk of bias (as defined by the authors using Cochrane guid-
ance). Amongst the four trials judged to be at low risk of bias,
calcium or calcium and vitamin D supplementation was asso-
ciated with a non-significant reduction in total fracture risk
[RR 0.96 (95 % CI 0.91, 1.01)]. In contrast, the studies judged
at moderate or high risk of bias, when meta-analysed by
group, demonstrated statistically significant reductions in frac-
ture risk with calcium or calcium and vitamin D supplemen-
tation. It should be noted however that 76 % of the 44,505
participants included in the low risk meta-analysis were con-
tributed by the WHI study, in which participants were permit-
ted personal use of calcium and vitamin D supplements; how-
ever, in another study, fracture reduction with calcium and
vitamin D supplementation was not evident in the WHI when
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stratified by personal use of supplements [22]. Overall, the RR
for all fractures and vertebral fractures were similar to those
obtained by Tang et al. [17] [all fractures RR 0.88 (95 % CI
0.83, 0.95); vertebral fracture RR 0.87 (95%CI 0.75, 1.01)] in
their meta-analysis. Additionally, in the Tang study, a statisti-
cally significant reduction in hip fractures was demonstrated
[RR 0.87 (95 % CI 0.75, 0.99)].
Trials included in the various meta-analyses derive partic-
ipants mainly from community settings with the minority
from institutions. The trial by Chapuy et al. [23], set in
French nursing/residential homes, has demonstrated the most
convincing fracture reductions with calcium and vitamin D
supplementation in a single study, and contrasts with the ab-
sence of any fracture reduction with either calcium, vitamin D,
or combination therapy for secondary fracture prevention in
the community-based RECORD study [24]. However, the in-
clusion of mainly community-dwelling participants in the
DIPART analysis suggests efficacy amongst community-
dwelling individuals. In the Bolland meta-analysis [20], the
reduction in all fractures with calcium and vitamin D supple-
mentation was similar in the 17 community-based trials [RR
0.88 (95 % CI 0.99, 0.98)] and the three trials based in resi-
dential care [RR 0.85 (95 % CI 0.74, 0.98)], p interac-
tion = 0.63. However, hip fracture reduction with calcium
and vitamin D supplementation was statistically significant
across 2 trials including residential patients [RR 0.75 (95 %
CI 0.62, 0.92)], but not in 11 trials including community-
dwelling participants [RR 1.10 (95 % CI 0.83, 1.46)], p inter-
action = 0.03. This is similar to Tang et al.’s meta-analysis
[17], in which calcium and vitamin D supplementation led
to a greater reduction in all fractures [RR 0.76 (95 % CI:
0.66, 0.88)] amongst institutionalised patients, than in
community-dwelling patients [RR 0.94 (95 % CI 0.90,
0.99), p interaction = 0.003]. It is important to note the relative
numbers though, with this analysis including 49,233
community-dwelling participants and 3392 institutionalised.
Conclusion: efficacy of calcium or calcium and vitamin D
supplementation for fracture reduction
Taken as a whole, the evidence base thus supports the use of
calcium in combination with vitamin D supplementation
rather than as the sole agent for reduction of fracture risk,
but with the magnitude of effect being modest. However,
efficacy has not been demonstrated for all individual fracture
types, or for calcium supplementation alone. Intervention is
probably best directed, therefore at those judged to be at
high risk of calcium/vitamin D deficiency. How this high-
risk population may be defined is much debated, and the
reader is referred to the guidance from the US Institute of
Medicine [25]. The role of routine calcium and vitamin D
supplementation as a population health strategy for fracture
prevention is not robustly supported.
Calcium and vitamin D supplementation
with anti-osteoporosis medication
The majority of medications for osteoporosis treatment, such
as bisphosphonates, are licenced in the context of calcium and
vitamin D repletion (Table 1), on the basis that the trials used
for the registration process almost always supplemented par-
ticipants with calcium and vitamin D, whether placebo or
treatment, most frequently as a fixed dose to all, but in a
minority to those with demonstrated deficiencies [26]. The
efficacy of anti-osteoporosis medications administered with-
out concomitant calcium and vitamin D is largely undocu-
mented, but has been demonstrated for clodronate [27], and
also for alendronate, although the latter in the context of die-
tary intake of ≥800 mg calcium per day and 400 IU vitamin D
daily [28]. The risk of vitamin D deficiency is important to
consider in differentiating osteomalacia from osteoporosis,
and thus the appropriate therapeutic approach. Dietary intake
is difficult to assess accurately, and in many cases the simplest
means of ensuring calcium and vitamin D repletion when
prescribing anti-osteoporosis medications is to issue adjunc-
tive supplementation.
Calcium, vitamin D and muscle function
Evidence is weak for calcium supplementation alone reducing
the decline of muscle mass and function, and fall risk with
ageing, except in the context of hypocalcaemia in which
muscle-related symptoms resolve after calcium or vitamin D
supplementation [29, 30]. There have been several
randomised controlled trials testing the effect of either vitamin
D alone or vitamin D in combination with calcium on skeletal
muscle strength, mass and power. A recent systematic review
with meta-analysis of these studies suggests a small but sig-
nificant positive effect of vitamin D supplementation on mus-
cle strength, without effect on muscle mass or muscle power
[31]. The effects were greater in those with baseline vitamin D
levels lower than 30 nmol/L, but there was no difference be-
tween vitamin D alone and combination of vitamin D with
calcium supplements.
Pre-clinical data on the role of calcium and vitamin D in
muscle physiology have provided a rationale for several
randomised controlled trials of vitamin D alone or in combi-
nation with calcium for fall prevention. High heterogeneity in
study populations, in vitamin D interventions (inactive or ac-
tive forms of vitamin D) and in falls reporting methods (num-
bers of falls or fallers) was observed in these studies. Twelve
successive meta-analyses (Table 2) have been performed on
this topic: nine of them concluded that vitamin D supplemen-
tation reduced the risk of falling (number of fallers −8 to
−22%) [32–40]. The Cochrane group meta-analysis of studies
in elderly people in hospitals and nursing care facilities
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identified a decrease in the rate of falls (−28 and −37 %, re-
spectively) but not of the number of fallers [41, 42]. In their
recent meta-analysis, Bolland et al. concluded that vitamin D
supplementation with or without calcium did not reduce the
number of falls by 15 % or more, this being their chosen
threshold for a minimally important clinical benefit [43].
Whether calcium may contribute to the effects of vitamin D
on fall prevention has been investigated in subgroups amongst
these studies. Several did not demonstrate any effect of calci-
um supplement co-administration [33, 36, 37, 41–43], whilst
two others found that the effect of vitamin D supplementation
on fall prevention was more prominent in patients in studies in
which calcium was co-administered with vitamin D [35, 38].
The additive value of calcium supplement co-administration
may be blunted in subjects with high dietary calcium intake,
which has not been taken into account in most of the studies.
In a study investigating the effects of 1α-hydroxyvitamin D,
only subjects with total dietary calcium intake above the me-
dian had a significant reduction in falls [44]. In addition, het-
erogeneity of effect was observed by baseline 25-
hydroxyvitamin D concentration [36, 38, 45, 46] and achieved
25-hydroxyvitamin D concentration [32] (except in the meta-
analysis of Bolland et al. [43]), suggesting that the effect of
vitamin D supplementation on fall reduction might be present
only in people with vitamin D deficiency and in those who
successfully achieve adequate 25-hydroxyvitamin D levels
with supplementation. In accordance with this interpretation,
and as recently highlighted by LeBlanc et al. in their meta-
analysis [36], the participants of a recent negative study on fall
prevention with 800 IU/day of vitamin D had mean baseline
25-hydroxyvitamin D concentrations of 26 to 28 ng/mL
(83 % > 20 ng/mL), which means that the majority had ade-
quate 25-hydroxyvitamin D concentrations [47]. Moreover,
two meta-analyses identified a vitamin D dose effect on fall
risk reduction [32, 35]. Finally, there is evidence that high
bolus doses of vitamin D might lead to increased risk of falls
[48–50], suggesting that daily supplemental approaches are
the preferred regimen.
Potential adverse effects of calcium supplementation
Renal stones and gastrointestinal side effects
Until the BMJ publication by Bolland et al. in 2008 [51], the
only potential adverse effects associated with calcium and
vitamin D supplementation had been an increased risk of renal
calculi and gastrointestinal symptoms. Indeed, a recent
Cochrane review has confirmed a modest increase in renal
stones [52], which is mainly informed by data from the
Women’s Health Initiative, demonstrating that the interven-
tion was associated with a 17 % increased risk of renal stones
(HR 95% CI 1.02, 1.34). It is important to note the magnitude
of this outcome in the context of the WHI study, given that
there was no statistically significant decrease in hip or other
fractures. The WHI investigators also examined the risk of
renal stones, stratified by use of personal supplements and
adherence to study medication [22]. In the subset who did
not use personal supplements, the hazard ratio for renal stones
with calcium and vitamin D supplementation was 1.08 (95 %
CI 0.88, 1.32); in the subset who did use personal supple-
ments, the hazard ratio was 1.23 (95 % CI 1.01, 1.48),
Table 1 Calcium and vitamin D supplementation as adjunctive therapy with medications for the treatment of osteoporosis
Drug Trial Calcium, mandatory If low Vit D, mandatory If low Supplemented
Run-in
No mandatory supplement
Alendronate FIT (Black, Lancet 1996) 500 mg 250 IU 82 % None
Calcium supplement mandatory
Risedronate VERT (Harris, JAMA 1999) 500 mg 500 IU 100 % None
Vitamin D supplement mandatory
Strontium SOTI (Meunier, NEJM 2004) <1000 mg 400+ IU 100 % 2–24 weeks
Calcium and vitamin D supplement mandatory
Raloxifene MORE (Ettinger, JAMA 1999) 500 mg 400+ IU 100 % None
Teriparatide Neer (NEJM 2001) 1000 mg 400+ IU 100 % None
Ibandronate BONE (Delmas, OI 2004) 500 mg 400 IU 100 % None
Zoledronic Acid HORIZON (Black, NEJM 2007) 1000+ mg 400+ IU 100 % None
PTH(1–84) TOP (Greenspan, Arch Int Med 2007) 700 mg 400 IU 100 % None
Bazedoxifen Silverman (JBMR 2008) <1200 mg 400+ IU 100 % None
Lasofoxifene PERL (Cummings, NEJM 2011) 1000 mg 400+ IU 100 % None
Information kindly provided by Professor Bo Abrahamsen, University of Southern Denmark
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although the interaction term was not statistically significant.
Within the personal supplements group, there was no differ-
ence in the hazard ratio for renal stones by adherence.
Gastrointestinal side effects have been relatively commonly
noted in trials of calcium supplementation. Such symptoms
include constipation, excessive abdominal cramping, bloating,
and, importantly, upper GI symptoms. Lewis et al. [53]
reviewed the risk of GI side effects across seven studies includ-
ed in Bolland et al.’s meta-analysis [54], and in which a pro-
portion of myocardial infarctions were self-reported. Overall,
the risk of GI side effects was increased by 43% in the calcium/
calcium and vitamin D groups [RR 1.43 (95 % CI 1.28, 1.59);
p < 0.001]. In absolute terms, 506 of 5046 (10 %) of patients
receiving placebo reported adverse GI events compared with
716 of 5082 (14.1 %) of patients receiving calcium supple-
ments. The authors did not identify any effect of the formula-
tion or dose of the calcium supplement, but did find evidence of
both upper and lower GI events being increased. Using the
adjudicated hospital admissions for GI complaints derived
from hospital discharge summaries in one Australian study,
6.8 % of calcium treated patients experienced a GI complaint
(n = 50) compared with 26 patients (3.6%) allocated to placebo
[RR 1.92 (95 % CI 1.21, 3.05); p = 0.006]. Thus, it is clear that
gastrointestinal side effects are an important consideration in
any strategy predicated on widespread use of calcium supple-
ments. Importantly, the authors hypothesised that self-reported
myocardial infarction may, in some cases, represent
misclassified gastrointestinal events. In the calcium only trials
of Bolland et al. [51], and Prince et al. [55], adjudicated and
self-reported myocardial infarction data were available. Across
the two studies there was an excess of self-reported myocardial
infarction in the calcium treated patients [RR 1.69 (95 % CI
1.09, 2.61); p = 0.02]. However, the risk of incorrect classifi-
cation of myocardial infarction was greater in the calcium than
in the placebo group [RR misreported myocardial infarction
2.44 (95 % CI 1.02, 5.87); p = 0.046], and thus, the RR for
adjudicated myocardial infarction was attenuated at 1.45
[(95 % CI 0.88, 2.45); p = 0.145]. The study demonstrates
the potential influence of misclassification of myocardial in-
farction secondary to self-report, a critically important consid-
eration in the evaluation of reported associations between cal-
cium supplementation and cardiovascular outcomes.
Initial evidence of potential cardiovascular effects
In their BMJ paper, Bolland et al. reported the adverse event
follow-up from a New Zealand randomised controlled trial of
calcium supplementation [51]. Amongst 1471 postmenopaus-
al women with a mean age of 74 years, who had been
randomised to either 1 g of elemental calcium citrate or pla-
cebo, incident cardiovascular events were self-reported and
adjudicated by review of medical records. The authors
analysed the events in terms of simple self-report, adjudicated
self-report, and then adjudicated events with additional (non-
participant reported) events from Health Registry data. A fur-
ther regression analysis adjusted for covariates. Table 3 sum-
marises the key findings from this and the other studies de-
scribed below.
The multiplicity of endpoints provided heterogeneous re-
sults [51]. There was an increased risk of self-reported myo-
cardial infarction in the calcium group versus the placebo
group [RR 2.24; (95 % CI 1.20, 4.17)], but there was a de-
creased risk of self-reported angina in the calcium group [RR
0.71 (95 % CI 0.50, 1.01)]. Outcomes including other chest
pain, transient ischaemic attack, stroke, and sudden death
were not statistically different by group and neither was the
combination of these outcomes. However, the composite end-
point of myocardial infarction, stroke, or sudden death was
statistically significantly increased in the calcium group [RR
1.66 (95 % CI 1.15, 2.40)]. Importantly, of 45 myocardial
infarction events in the calcium and 19 in the placebo group,
only 24 and 10, respectively, were verified through the adju-
dication process. For the composite endpoint of myocardial
infarction, stroke, or sudden death, the adjudicated numbers
dropped from 101 self-reported to 61 adjudicated events in the
calcium group and 54 self-reported to 36 adjudicated events in
the placebo group and the difference in rates of adjudicated
composite outcome was not statistically significant. The dif-
ference in rate of adjudicated myocardial infarction by group
also weakened with the lower band of the 95 % CI at 1.01
(p = 0.047). In the next analysis, which included adjudicated
events and those collected from the national database of hos-
pital admissions in New Zealand, there appeared to be no
statistically significant differences between calcium and pla-
cebo groups for any of the outcomes apart from the composite
outcome of myocardial infarction, stroke or sudden death, but
here only when calculated as a rate ratio (p = 0.043) rather
than a difference in event numbers. After adjustment for a
variety of covariates, calcium or placebo allocation did not
appear to be associated with risk of the composite outcome
of myocardial infarction, stroke, or sudden death. The mes-
sage of increased cardiovascular risk from calcium supple-
mentation that was widely taken from this paper rests very
much on the analysis of self-reported events, which were not
the primary outcomes of the study. Indeed, the findings were
not supported by the further analysis reported in the manu-
script, points which seem to be have been largely ignored in its
interpretation.
Meta-analyses of calcium (and vitamin D)
supplementation and cardiovascular outcomes
This initial paper was followed by a meta-analysis of
randomised trials of calcium supplementation [54] combining
8151 persons in a patient level analysis, in which the
RECORD study provided two thirds of the cases and two
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thirds of the myocardial infarction events. Secondly, the au-
thors undertook a trial-level analysis of 11,921 participants,
the RECORD study providing 44 % of the cases and 55 % of
the myocardial infarction events. In the patient-level analysis,
there was an increased risk of myocardial infarction, of bor-
derline statistical significance [HR 1.31 (95 % CI 1.02, 1.67);
p = 0.035] but not of stroke or death, or of the composite
outcome including all three [HR 1.18 (95 % CI 1.00, 1.39);
p = 0.057]. There was a statistically significant interaction
between treatment and baseline dietary calcium intake, which
was only observed for the outcome of myocardial infarction.
Thus, the treatment-myocardial infarction association ap-
peared to be stronger above than below the median calcium
intake of 825 mg per day, but there was no similar interaction
for the other outcomes; there was no consistent increase in the
hazard ratio for myocardial infarction associated with calcium
supplementation by fifths of dietary calcium intake. In the
trial-level analysis, differences were similar but even smaller
[myocardial infarction, HR 1.27 (95 % CI 1.01, 1.59);
p = 0.038; and composite endpoint, HR 1.12 (95 % CI 0.97,
1.30); p = 0.13]. Although all events were adjudicated blind
by the investigators, the included studies recorded cardiovas-
cular outcomes in different ways with some using self-report
(including RECORD), some hospital records and some death
certificates. Furthermore, although the analyses were based on
prior hypotheses, they remain secondary to the primary anal-
yses of the individual trials, and the results reflect a consider-
able number of statistical tests, with the majority hovering
around the p = 0.05 threshold. Whilst these events could be
viewed as safety outcomes, which in the context of a
randomised controlled trial would not be subject to any con-
sideration of multiple testing (on a primum non nocere basis),
the authors specifically talk in terms of ‘prespecified primary
endpoints’, and in the context of a meta-analysis, it is arguable
whether the principle of safety reporting as applied to a single
trial is still appropriate. It is notable that any adjustment for
multiple testing would almost certainly render all findings
non-significant.
Table 3 Summary of cardiovascular associations with calcium (and vitamin D) supplementation
Study Trial level/IPDa Total n Outcome HR (95 % CI) p value
Bolland 2008
Calcium only
Single trial 1471 Angina 0.71 (0.50, 1.01) 0.058
Self-reported Myocardial infarction 2.24 (1.20, 4.17) 0.0099
Stroke 1.44 (0.9, 2.31) 0.14
Sudden death 4.04 (0.45, 36.0) 0.22
Angina, chest pain, myocardial
infarction, sudden death
0.94 (0.72, 1.24) 0.68
Myocardial infarction, stroke,
sudden death
1.66 (1.15, 2.40) 0.0075
Verified Myocardial infarction 2.12 (1.01, 4.47) 0.047
Stroke 1.42 (0.83, 2.43) 0.21
Sudden death 1.01 (0.20, 4.99) 1.0
Myocardial infarction, stroke,
sudden death
1.47 (0.97, 2.23) 0.076
Verified, including additional registry data Myocardial infarction 1.49 (0.86, 2.57) 0.16
Stroke 1.37 (0.83, 2.28) 0.23
Sudden death 0.51 (0.13, 2.01) 0.51
Myocardial infarction, stroke,
sudden death
1.21 (0.84, 1.74) 0.32
Bolland 2010
Calcium only
Verified and
self-reported events
IPD 8151 Myocardial infarction 1.31 (1.02, 1.67) 0.035
Stroke 1.20 (0.96, 1.50) 0.11
Death 1.09 (0.96, 1.23) 0.18
Myocardial infarction/stroke/death 1.18 (1.00, 1.39) 0.057
Trial level 6116 Myocardial infarction 1.27 (1.01, 1.59) 0.038
Stroke 1.12 (0.92, 1.36) 0.25
Death 1.07 (0.95, 1.19) 0.26
Myocardial infarction/stroke/death 1.12 (0.97, 1.30) 0.13
Bolland 2011
Calcium/calcium and vitamin D
Verified and self-reported
events
IPD 24,869 Myocardial infarction 1.26 (1.07, 1.47) 0.005
Stroke 1.19 (1.02, 1.39) 0.03
Myocardial infarction/stroke 1.17 (1.05, 1.31) 0.005
Trial level 28,072 Myocardial infarction 1.21 (1.01, 1.44) 0.04
Stroke 1.20 (1.00, 1.43) 0.05
Myocardial infarction/stroke 1.16 (1.02, 1.32) 0.02
Lewis 2014
Calcium/ calcium and vitamin D
All verified events
Trial level 48,460 Coronary heart disease 1.02 (0.96, 1.09 0.51
Myocardial infarction 1.08 (0.93, 1.25) 0.37
Angina/acute coronary syndrome 1.09 (0.95, 1.24) 0.22
Chronic coronary artery disease 0.92 (0.73, 1.15) 0.46
a Trial level or individual patient data (IPD) meta-analysis
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The suggestion of an interaction between treatment and
baseline calcium intake is intriguing given findings from a
re-analysis of the WHI study, undertaken by the same group
in 2011. They also included the WHI study in their second
meta-analysis, investigating both calcium and vitamin D sup-
plementation [56]. In this paper, the authors used the WHI
calcium and vitamin D study public access dataset to investi-
gate the effect of calcium and vitamin D supplementation
versus placebo in 36,282 community-dwelling postmeno-
pausal women. The WHI allowed women to take personal
calcium and vitamin D supplementation in addition to the
study medication, and the authors reasonably hypothesised
that this might modify the effect of the trial medication.
They therefore stratified their analysis by personal calcium
and vitamin D supplementation and found that there was a
statistically significant interaction between personal use of
supplements and allocation to calcium and vitamin D or pla-
cebo for cardiovascular events. However, the importance of
this interaction is unclear, given that very few of the associa-
tions in either group, between treatment and placebo, with
cardiovascular or cerebrovascular outcomes, were statistically
significant. Indeed, the only association which attained a p
value of <0.05 is that with clinical myocardial infarction or
re-vascularisation in the group who did not use personal cal-
cium supplementation. The composite outcome of myocardial
infarction, coronary heart disease, death or revascularisation
(differing from the composite outcome used in the previous
meta-analysis) was non-significant at p = 0.07, and there was
no difference in death from all causes. In fact, amongst those
who were using personal calcium supplementation, death
from all causes was actually greater in the placebo group
(p = 0.01). Although not statistically significant, both stroke
and the composite outcome of clinical myocardial infarction
or stroke were less frequent in those allocated to calcium and
vitamin D who were taking personal supplements.
Furthermore, there was no evidence of a dose effect according
to personal calcium supplementation ranging from 0 to above
1000 mg per day.
The addition of the WHI data into a trial-level meta-
analysis with two other studies of calcium and vitamin D
demonstrated a 21 % increased risk of myocardial infarc-
tion with calcium and vitamin D supplementation (RR
95 % CI 1.01, 1.44; p = 0.04) with a similar but border-
line difference in stroke (p = 0.05) and a statistically sig-
nificant increase for the combination of the two outcomes
[RR 1.16 (95 % CI 1.02, 1.32); p = 0.02]. Findings from
a patient-level data meta-analysis including 24,869 partici-
pants from five trials of calcium/vitamin D supplementa-
tion, and the WHI calcium and vitamin D study partici-
pants who were not taking personal supplements at base-
line, demonstrated an increased risk of myocardial infarc-
tion [HR 1.26 (95 % CI 1.07, 1.47); p = 0.005] and
stroke [HR 1.19 (95 % CI 1.02, 1.39); p = 0.03] and
the combined outcome, but not for death from any cause
(p = 0.5) [56].
These two meta-analyses and the original study come with
a number of concerns, including the heterogeneity of event
reporting, that cardiovascular events were not the primary
outcome of any included study, that the majority of findings
are of borderline statistical significance, that potentially bene-
ficial effects of similar magnitude have not been emphasised,
and that the issue of correction for multiple testing in the
secondary analyses has also not been adequately addressed.
The lack of dose-response in relation to baseline intake in the
WHI study, and the suggestion of opposing effects of baseline
dietary intake in the first meta-analysis and personal supple-
mentary intake in WHI are also troubling, as it is difficult to
envisage a biological mechanism whereby such a difference
could occur.
Lewis et al. recently undertook a similar meta-analysis to
those of Bolland et al., combining trial-level data on 63,563
female participants, obtained from published and unpublished
results [57]. The authors focused on women as there are in-
sufficient men in the original trials to form valid conclusions,
and the greater rates of cardiovascular events in men than
women may lead to erroneous conclusions if randomisation
to calcium/placebo is not balanced by sex. The authors also
used only trials in which coronary heart disease endpoints
were validated and used ICD-based definitions which are
globally recognised and encompass different components of
coronary heart disease. Given the risk of gastrointestinal side
effects with calcium supplements, and that these may be
misclassified as cardiovascular events (see above) [53], such
adjudication is essential. Furthermore, previous assessments
of the validity of self-reported cardiovascular events have
demonstrated that confirmation may only be achieved in 60–
70 % of cases [58, 59]. Bolland et al. also undertook an anal-
ysis excluding self-reported outcomes (i.e. limiting the analy-
sis to validated myocardial infarction) [60]. Although these
results were similar to those from the 2010 meta-analysis (in
which 23 % of events were ascertained by self-report) [54], it
is unclear in this secondary analysis, published in a review
article, as to exactly which trials were included in which anal-
ysis. In the Lewis study, overall, there was no effect of
calcium/calcium and vitamin D supplementation on myocar-
dial infarction [RR 1.08 (95 % CI 0.93, 1.25)]; angina
pectoris/acute coronary syndrome [RR 1.09 (95 % CI 0.95,
1.24)] or chronic coronary heart disease [RR 0.92 (95 % CI
0.73, 1.15)]. In sensitivity analyses, the investigators observed
no relationship between supplementation with calcium/
calcium and vitamin D and coronary heart disease or all-
cause mortality. However, supplementation with calcium
alone was associated with a 37 % increase in myocardial in-
farction [RR 1.37 (95 % CI 0.98, 1.92)], a finding which was
not statistically significant (p = 0.07) and was based on 139
myocardial infarctions in 6333 participants compared with
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estimates of the effect of calcium with vitamin D based on
1006 events in 45,796 participants. This meta-analysis, unlike
the Bolland meta-analyses, included a cluster randomised trial
by Larsen et al. [61]. However, further sensitivity analyses
demonstrated no difference in the findings when cluster
randomised trials were excluded. Whilst the authors did not
specifically test for an interaction with personal calcium and
vitamin D supplement use in the WHI study, a sensitivity
analysis in which the WHI participants using personal supple-
mentation at baseline were excluded yielded very similar re-
sults overall. This meta-analysis therefore does not support the
finding from Bolland et al. of a specific effect within those not
taking personal calcium and vitamin D supplementation.
Whilst the findings of the Lewis et al. meta-analysis are large-
ly reassuring, the non-statistically significant association for
calcium supplementation alone for myocardial infarction
should be noted, albeit based on a subgroup with a relatively
small number of events, and no consistent effect on coronary
heart disease or mortality. Furthermore, none of the meta-
analyses have been able to address the associations in men,
due to the small number of males in the constituent trials.
An earlier meta-analysis fromMao et al. identified 11 trials
of calcium or vitamin D or both [62]. The relationships are
presented in terms of odds ratios, despite being derived from
randomised trials. The authors also present, for the primary
analyses, associations between vascular outcomes and supple-
mentation with calcium, vitamin D or both, and thus conflat-
ing two different questions. However, in secondary analyses
of calcium supplementation alone, again based on a small
subset of participants, the odds ratio for myocardial infarction
was 1.28 (95 % CI 0.97, 1.68); p = 0.08, compared with
placebo. The odds ratio for myocardial infarctionwith calcium
plus vitamin D supplementation was 1.06 (95 % CI 0.92,
1.21); p = 0.43. The authors also noted differences in the
calcium/vitamin D associations with myocardial infarction
by sex, with a much greater odds ratio in men than women,
but relationships in either sex were not statistically significant
(p = 0.27 in women and p = 0.41 in men); importantly, the
findings were based on 3828 men compared with 46,424
women. Again, the exact trials included varied from the other
meta-analyses, and Mao et al. did not consider the WHI par-
ticipants stratified by personal calcium use.
The WHI study has been analysed by its own investigators
who, in an initial follow-up 8 years from randomisation, found
no increased risk of myocardial infarction/coronary death or
stroke with hazard ratios near one [63]. A comprehensive
subgroup analysis demonstrated no increases in cardiovascu-
lar events with supplementation [22]. Importantly, in the study
by Prentice et al., the analysis was stratified by use of personal
supplementation. There was no increased risk of myocardial
infarction with calcium and vitamin D supplementation in
either the whole trial population [HR 1.03 (95 % CI 0.90,
1.19)], in those who took personal supplements [HR 0.97
(95 % CI 0.80, 1.17)] or in those who took no personal sup-
plementation [HR 1.11 (95 % CI 0.90, 1.37)], and no statisti-
cally significant difference in the hazard ratios between the
strata. Interestingly, the risks of myocardial infarction, coro-
nary heart disease and other outcomes were analysed by time
from randomisation, with no evidence of any statistically sig-
nificant change in the hazard ratio with increasing follow-up
time. Although the hazard ratios for myocardial infarction
within the first 2 years after randomisation were greater than
unity within all participants [HR 1.19 (95 % CI 0.89, 1.59)]
and amongst those who did not take personal supplements
[HR 1.30 (95 % CI 0.86, 1.97)], these were not statistically
significant, and over years 2–5, the hazard ratios were close to
unity [all participants HR 0.97 (95 % CI 0.78, 1.21); no per-
sonal supplements, HR 1.04 (95 % CI 0.74, 1.47)], with a
similar null relationships at >5-year follow-up. Although
clearly limited by variable adherence to medication over the
study period, this absence of any time relationship (if any-
thing, there was a decreasing risk with time) with myocardial
infarction or other coronary outcomes seems incompatible
with any biological mechanism which requires increase in
coronary atherosclerosis related to raised calcium concentra-
tions. A further follow-up at up to 5 years after cessation of
trial medication again provided reassuring results, finding no
difference in coronary heart disease endpoints over 15 years of
follow-up in 29,862 women [64], although this was not strat-
ified by use of personal supplements.
Calcium (and vitamin D) supplementation and risk
of death
It would seem intuitively reasonable that if an intervention
leads to an increased risk of a potentially fatal event such as
myocardial infarction, then over a reasonable period of time
in a large cohort, it would also be associated with an in-
creased risk of death from that cause. Interestingly, to our
knowledge, no study has yet demonstrated such an associa-
tion. Whilst the first meta-analysis by Bolland et al. [54]
demonstrated a non-significant 7 % increase in mortality
with calcium supplementation (RR 95 % CI 0.95, 1.19),
in their WHI analysis [56], there was no effect on death
amongst the population not using personal calcium/vitamin
D supplements [RR 0.99 (95 % CI 0.86, 1.14)]. Amongst
those using personal calcium supplements, calcium and vi-
tamin D supplementation was associated with a reduced risk
of death [RR 0.84 (95 % CI 0.73, 0.97)]. Furthermore, in a
subset of the WHI participants who underwent computed
tomography examination of coronary artery calcification at
a mean of 7 years follow-up (754 women aged 50–59 years
at baseline), there was no difference in coronary artery cal-
cification score according to calcium and vitamin D treat-
ment versus placebo [65]. In their meta-analysis using
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verified outcomes, Lewis et al. demonstrated no effect of
calcium supplementation on mortality [57], a finding similar
to that of the DIPART investigators [66], who demonstrated
no difference in mortality in an individual patient data meta-
analysis of eight studies including RECORD and WHI, and
a trial-level analysis including a further 16 studies. Again,
data from the Women’s Health Initiative demonstrated
reassuring findings with mortality somewhat lower in the
calcium and vitamin D group compared with placebo [HR
0.91 (95 % CI 0.83, 1.01)], and this result was similar when
examined in those below or above 70 years old. Follow-up
of the RECORD study of 5292 participants over 70 years
old, who had previously experienced a low trauma fracture
[67], demonstrated no effect of calcium supplementation on
mortality in an intention-to-treat analysis [all-cause mortality
HR 1.03 (95 % CI 0.94, 1.13); vascular disease mortality
HR 1.07 (95 % CI 0.92, 1.24)]. In a secondary analysis
adjusting for treatment received (thus with a reduced num-
ber of participants), calcium supplementation again was not
statistically significantly associated with all-cause mortality
or vascular death, although the hazard ratios were greater
than in the ITT analysis [all-cause mortality HR 1.21 (95 %
CI 0.83, 2.05); vascular death HR 1.43 (95 % CI 0.75,
7.61)]. The trial therefore does not provide support either
way [67]. Given that the increased risk of myocardial in-
farction associated with calcium supplementation in the
Bolland meta-analyses is relatively modest, and that not all
myocardial infarctions result in death, it is possible that
existing studies are simply not large enough to detect an
effect on mortality [60].
Mechanistic considerations
The mechanisms by which calcium supplementation might
increase cardiovascular risk have been much debated. A key
argument proposed in favour of a mechanistic link is that the
transient rise in serum calcium concentrations consequent to
ingestion of a calcium supplement might lead to increased
calcium deposition within coronary artery walls [68]. Indeed,
calcification is a recognised component of atherosclerotic dis-
ease. However, the increase in serum calcium resulting from
supplement ingestion is transient and of modest magnitude,
and well below concentrations which would lead to calcium
× phosphate saturation [69]. Since tissues sense calcium ions,
rather than their source (i.e. calcium intake from supplementa-
tion is not sensed differently to that from food), any mecha-
nism of action would likely be related to this transient increase
in concentrations [69]. Whilst there is, to our knowledge, no
direct evidence that such transient increases in calcium concen-
tration cause greater coronary calcification or ischaemic cardi-
ac events, there is evidence from observational studies that, at
the population level, serum calcium and/or phosphorus
concentrations are positively related to risk of ischaemic cardi-
ac events [70–77]. Evidence linking serum calcium concentra-
tions to coronary calcification is mixed. Thus, there was a weak
positive cross-sectional association between calcium × phos-
phorus product and coronary artery calcification score (byCT),
amongst 384 patients with metabolic syndrome (although ap-
parently not amongst 1672 patients without metabolic syn-
drome) [78]. In a larger cross-sectional study of 1088
middle-aged men and women, serum total calcium concentra-
tions were again positively associated with coronary artery
calcification score, but only amongst men and not women
[79]. This sex discordance is the opposite of the findings from
Rohrmann et al. in relation to incident ischaemic cardiovascu-
lar events in a large prospective database study of 441,738
participants, in which serum calcium concentrations (corrected
for albumin concentrations) were positively related to risk of
incident myocardial infarction, non-fatal cardiovascular dis-
ease, and stroke during a median follow-up time of 21 years
[77]. The effect sizes were modest, e.g. a 19 % increase in
myocardial infarction comparing top with bottom fifth of se-
rum corrected calcium concentration, and here effects were of
greater magnitude in women than men. A further study dem-
onstrated associations between serum phosphorus concentra-
tions and coronary atherosclerosis in young adults [80]. These
studies clearly differ markedly in predictor (calcium × phos-
phate product, total calcium, corrected calcium, serum phos-
phorus), outcome (coronary artery calcification, clinical event)
and study design (cross-sectional, prospective database); the
possibility of confounding and/ or reverse causation remain
important considerations in these as in earlier investigations.
The one trial (WHI) to address this issue mechanistically with
assessment of coronary artery calcification by CT demonstrat-
ed no excess of coronary calcification with calcium and vita-
min D supplementation [65].
These observational findings might suggest that chronical-
ly higher serum calcium and/or phosphorus concentrations are
associated with higher rates of ischaemic cardiac events. It is
extremely unclear though whether such associations have any
bearing on the transient rises in calcium consequent to inges-
tion of a calcium supplement. The opposing effects of chron-
ically vs transiently elevated parathyroid hormone on bone
provide an instructive example in this regard. Indeed, daily
recombinant parathyroid hormone injection, as therapy for
osteoporosis, leads to a transient rise in serum calcium con-
centrations with each dose [81], but the randomised trial evi-
dence, observational studies and postmarketing surveillance
data have not demonstrated any concerning signals related to
myocardial infarction or other ischaemic cardiac events [82,
83]. A further important point is the positive relationship ob-
served between ischaemic cardiac events and both calcium
and phosphorus concentrations. As described below, calcium
supplements have phosphate-binding properties, and therefore
supplementation with calcium is likely to have a lowering
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effect on phosphorus concentrations; we are not aware of any
data suggesting differences in calcium supplement-
myocardial infarction relationships by supplement type.
Finally, the recent concerns regarding strontium ranelate in
relation to myocardial infarction have been used to support a
causal role of calcium in ischaemic heart disease, given its
similarity to strontium in terms of atomic structure [60]. A
close inspection of the basis on which this recommendation
was made suggests that whilst it is a reasonable step in terms
of drug safety, there is minimal evidence to support a causal
relationship [84]; indeed, we identified scant other data sug-
gesting any role of strontium in the pathogenesis of cardiovas-
cular disease.
Importantly, the primary abnormality in the development
of atherosclerosis is thought to be pathological intimal thick-
ening, with atherosclerotic plaques forming at sites of endo-
thelial damage, rather than exposure to circulating calcium.
Indeed, calcification of plaques appears to be related to mac-
rophage apoptosis leading to microcalcifications, which may
coalesce [85]. If there were a causal link between calcium
supplementation and atherosclerosis, then it might be via other
cardiovascular risk factors, but there is little evidence for this.
Where there have been associations, such as with blood pres-
sure and lipid profile, these have generally been protective
[86–90]. Furthermore, whilst there is evidence that calcium
supplementation (in phosphate binders) is associated with in-
creased risk of myocardial infarction and death in end-stage
renal failure, it is important to appreciate that chronic renal
failure leads to a highly perturbed metabolic milieu, in which
endothelial dysfunction is an important component [91].
Thus, in a study comparing arterial wall calcification in ves-
sels from healthy and chronic renal failure patients, exposure
to raised calcium concentrations had no effect on arterial wall
calcification in the healthy tissue, but led to increased calcifi-
cation in the vessels of chronic renal failure patients [92]. The
degree of renal failure at which calcium supplementation
might become problematic has not been defined. This is an
important question, because of the large number of elderly
individuals who have mild to moderate renal impairment.
The question of whether cardiovascular risk might be raised
by calcium supplements specifically in those with pre-existing
ischaemic cardiovascular disease remains unanswered.
Further work is clearly needed to investigate these mechanis-
tic aspects, but whilst the evidence to date suggests calcium
supplementation in end-stage renal failure increases cardio-
vascular risk, there is no direct evidence of a causal link in
healthy individuals.
Conclusions
The available evidence suggests that calcium given with vita-
min D supplementation leads to a modest reduction in the risk
of future fracture, and that the evidence is most robust for
those individuals at high risk of deficiency in these nutrients.
There is less evidence to support the routine supplementation
of older individuals dwelling in the community, and therefore,
supplementation is best targeted to those at highest risk.
Calcium and vitamin D supplementation is also recommended
for those individuals receiving therapies for osteoporosis such
as bisphosphonates, given the scant evidence to support the
use of anti-osteoporosis interventions without concomitant
calcium and vitamin D administration. The use of calcium-
containing supplements must be considered in the context of
the increased risk of renal stones, and of gastrointestinal side
effects, which can be severe enough to warrant hospital ad-
mission. In contrast, the evidence for cardiovascular events
occurring as a consequence of calcium and vitamin D supple-
mentation is unpersuasive. Considerations such as the pres-
ence of a signal for myocardial infarction but not for other
cardiovascular outcomes and not for death; the borderline sta-
tistical significance and lack of consideration for multiple test-
ing in secondary analyses of randomised control trials in
which cardiovascular endpoints were not primary outcomes
and which were of heterogeneous ascertainment and valida-
tion; the inconsistent risk profile and interaction between
background calcium intake and trial medication; and the lack
of an established direct linking mechanism [69], are all serious
caveats to the assertion that calcium supplementation (with or
without vitamin D) leads to increased cardiovascular risk. A
large randomised trial of calcium supplementation with adju-
dicated cardiovascular endpoints will be required to properly
answer this issue. An argument against this strategy is the
potential ethical concern over a trial in which the outcome is
an adverse event. However, given the continued uncertainty
over the role of calcium supplementation alone for fracture
reduction, a WHI-style trial, but in which personal calcium
supplementation were not permitted, powered to detect a re-
duction in fractures and any increase in validated cardiovas-
cular outcomes, might well offer a practicable way forward.
Summary points
1. Calcium and vitamin D supplementation leads to amodest
reduction in fractures, but use of calcium supplementation
alone is not robustly supported.
2. The evidence for calcium and vitamin D supplementation
for fracture reduction is most robust in those who are
likely to be at greatest risk of calcium and/or vitamin D
insufficiency; population-based interventions have not
convincingly demonstrated benefit.
3. Although calcium is intimately involved in muscle phys-
iology, the best clinical evidence suggests that vitamin D
optimisation, rather than supplementation with calcium,
leads to reduced risk of falls.
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4. Calcium supplements are associated with gastrointestinal
side effects and a small increased risk of renal stones.
5. The assertion that calcium with vitamin D supplementa-
tion increases cardiovascular risk is based on inadequate
evidence; several studies demonstrate the converse or no
cardiovascular effect.
6. A large randomised control trial of calcium supplementa-
tion powered to detect validated fractures and cardiovas-
cular events is required to ultimately clarify this issue.
7. On the basis of the current evidence, we recommend that
calcium and vitamin D supplements are generally appro-
priate for those with a high risk of calcium and vitamin D
insufficiency and in those who are receiving treatment for
osteoporosis.
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